Cochrane Evidence Synthesis and Methods ►

Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

To assess the efficacy and safety of PD-1 inhibitors or PD-L1 inhibitors plus chemotherapy compared with chemotherapy for people with early triple-negative breast cancer.

This is a protocol.

Published:

26 September 2022

Authors:

Gao Y, Liu M, Li L, Zhang J, Song F, Tian J

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Gao Y, Liu M, Li L, Zhang J, Song F, Tian J. Immune checkpoint inhibitors and chemotherapy versus chemotherapy for early triple-negative breast cancer (Protocol). Cochrane Database of Systematic Reviews 2022, Issue 9. Art. No.: CD015072. DOI: 10.1002/14651858.CD015072.